WO2003040211A2 - Branched polymers and their conjugates - Google Patents
Branched polymers and their conjugates Download PDFInfo
- Publication number
- WO2003040211A2 WO2003040211A2 PCT/US2002/035759 US0235759W WO03040211A2 WO 2003040211 A2 WO2003040211 A2 WO 2003040211A2 US 0235759 W US0235759 W US 0235759W WO 03040211 A2 WO03040211 A2 WO 03040211A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- polymer
- group
- branched
- branched polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Definitions
- This invention relates to branched, reactive water soluble polymers useful for conjugating to biologically active molecules and to methods for making and utilizing such polymers.
- the total molecular weight of the polymer or polymers attached to the biologically active molecule must be sufficiently high to impart the advantageous characteristics typically associated with PEG polymer attachment, such as increased water solubility and circulating half life, while not adversely impacting the bioactivity of the parent molecule.
- Proteins and other molecules often have a limited number of reactive sites available for polymer attachment. Often, the sites most suitable for modification via polymer attachment play a significant role in receptor binding, and are necessary for retention of the biological activity of the molecule. As a result, indiscriminate attachment of polymer chains to such reactive sites on a biologically active molecule often leads to a significant reduction or even total loss of biological activity of the polymer-modified molecule.
- To form conjugates having sufficient polymer molecular weight for imparting the desired advantages to a target molecule prior art approaches have typically involved either (i) random attachment of numerous polymer arms to the molecule, thereby increasing the risk of a reduction or even total loss in bioactivity of the parent molecule, or (ii) attachment of one or two very long polymer chains. Unfortunately, the use of very high molecular weight linear polymer chains is problematic because of the difficulty and expense associated with their preparation, purification, and associated instability.
- Branched polymers comprising a plurality of polymer arms attached to a central core and having a single reactive group for conjugation to a biologically active molecule have been described in U.S. Patent Nos. 5,643,575 and 5,932,462. Both patents describe branched polymers formed by covalent attachment of a water-soluble polymer such as an end-capped PEG to a central core molecule bearing amino groups, such as lysine or l,3-diamino-2-propanol.
- branched polymers are useful for attaching a high molecular weight polymer to a molecule at a single attachment site without using an extremely long polymer chain
- the methods of forming the branched PEG molecules of the prior art is difficult and requires extensive purification of the PEG polymers prior to attachment to the core molecule and also purification removal of partially pegylated polymer intermediates.
- the present invention is based upon the development of branched, reactive water-soluble polymers useful for conjugation to biologically active molecules in a manner that tends to avoid a significant reduction in the biological activity of the molecule while still providing the benefits of water-soluble polymer conjugation.
- the branched polymers of the invention can be readily synthesized from a number of aliphatic core structures that do not require the presence of activating groups suitable for coupling to an activated linear polymer, such as succinimidyl carbonate end- capped poly(ethylene glycol) or the like, for building the branched water soluble polymer.
- the preparation of the polymers of the invention is not hampered by the need to utilize core structures having reactive functional groups necessary for coupling with the polymer arms, since the polymer portions of the molecule are generally built directly onto the core by polymerization of suitable monomer units.
- the present invention provides a branched, reactive water- soluble polymer comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central core molecule through heteroatom linkages such as ether linkages.
- the central core molecule is an aliphatic hydrocarbon having a length of at least three carbon atoms.
- the branched polymers of the invention are preferably although not necessarily monofunctional (i.e., having one reactive functional group suitable for covalent attachment to a biologically active agent), and the single functional group is preferably attached, optionally via an intervening linkage, to the aliphatic hydrocarbon core molecule.
- Suitable polymers for use in preparing the branched polymer structures of the invention include poly(alkylene glycols), poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly( ⁇ -hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), poly(acrylic acid), carboxymethyl cellulose, hyaluronic acid, hydroxypropylmethyl cellulose, and copolymers, terpolymers, and mixtures thereof.
- the polymer is a poly(ethylene glycol).
- the invention provides a biologically active conjugate comprising a biologically active molecule, such as a protein, covalently attached to a branched polymer as described above.
- the biologically active molecule is preferably attached to the branched polymer via a linkage formed by reaction of a reactive functional group on the branched polymer with a suitable functional group on the biologically active molecule.
- the invention provides a method of preparing branched reactive polymers comprising poly(alkylene glycol) polymer arms.
- the method includes polymerization of alkylene oxide monomer units, such as ethylene oxide, onto an aliphatic hydrocarbon core structure bearing at least two nucleophilic groups (e.g., thiol, amino or hydroxyl groups).
- the nucleophilic groups are identical such as in propane substituted with hydroxyl groups at the 1- and 3 -positions (1,3-propanediol) to, for example, favor polymerization rates that are comparable in each of the polymer arms.
- At least one reactive group suitable for further modification is also attached to the aliphatic hydrocarbon core, optionally via an intervening linkage.
- the protecting group of the protected hydroxyl or other functional group is removed to provide a reactive group suitable for further modification, e.g., to form a branched polymer suitable for direct covalent attachment to a biologically active molecule to form a branched polymer conjugate.
- active ester would include those esters that react readily with nucleophilic groups such as amines.
- exemplary active esters include N-hydroxysuccinimidyl esters or 1- benzotriazolyl esters.
- an active ester will react with an amine in aqueous medium in a matter of minutes, whereas certain esters, such as methyl or ethyl esters, require a strong catalyst in order to react with a nucleophilic group.
- functional group includes protected functional groups.
- protected functional group or “protecting group” or “protective group” refers to the presence of a moiety (i.e., the protecting group) that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions.
- the protecting group will vary depending upon the type of chemically reactive group being protected as well as the reaction conditions to be employed and the presence of additional reactive or protecting groups in the molecule, if any.
- Protecting groups known in the art can be found in Greene, T.W., et al., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 3rd ed., John Wiley & Sons, New York, NY (1999).
- linkage or "linker” (L) is used herein to refer to an atom or a collection of atoms used to link, preferably by one or more covalent bonds, interconnecting moieties such as two polymer segments or a terminus of a polymer and a reactive functional group present on a bioactive agent.
- a linker of the invention may be hydrolytically stable or may include a physiologically hydrolyzable or enzymatically degradable linkage.
- a “physiologically hydrolyzable” or “hydrolytically degradable” bond is a weak bond that reacts with water (i.e., is hydrolyzed) under physiological conditions. Preferred are bonds that have a hydrolysis half life at pH 8, 25 °C of less than about 30 minutes. The tendency of a bond to hydrolyze in water will depend not only on the general type of linkage connecting two central atoms but also on the substituents attached to these central atoms.
- Appropriate hydrolytically unstable or degradable linkages include but are not limited to carboxylate ester, phosphate ester, anhydrides, acetals, ketals, acyloxyalkyl ether, imines, orthoesters, peptides and oligonucleotides.
- a “hydrolytically stable” linkage or bond refers to a chemical bond, typically a covalent bond, that is substantially stable in water, that is to say, does not undergo hydrolysis under physiological conditions to any appreciable extent over an extended period of time.
- hydrolytically stable linkages include but are not limited to the following: carbon-carbon bonds (e.g., in aliphatic chains), ethers, amides, urethanes, and the like.
- a hydrolytically stable linkage is one that exhibits a rate of hydrolysis of less than about 1-2% per day under physiological conditions. Hydrolysis rates of representative chemical bonds can be found in most standard chemistry textbooks.
- An "enzymatically unstable" or degradable linkage is a linkage that can be degraded by one or more enzymes.
- polymer backbone refers to the covalently bonded chain of repeating monomer units that form the polymer.
- the terms polymer and polymer backbone are used herein interchangeably.
- the polymer backbone of PEG is
- the polymer backbone may be covalently attached to terminal functional groups or pendant functionalized side chains spaced along the polymer backbone.
- reactive polymer refers to a polymer bearing at least one reactive functional group.
- M n NiMi average molecular weight
- alkyl refers to hydrocarbon chains typically ranging from about 1 to about 12 carbon atoms in length, preferably 1 to about 6 atoms, and includes straight and branched chains. Unless otherwise noted, the preferred embodiment of any alkyl or alkylene referred to herein is Cl-C6alkyl
- Cycloalkyl refers to a saturated or unsaturated cyclic hydrocarbon chain, including bridged, fused, or spiro cyclic compounds, preferably comprising 3 to about
- Aryl means one or more aromatic rings, each of 5 or 6 core carbon atoms.
- aryl rings may be fused, as in naphthyl or unfused, as in biphenyl.
- Aryl rings may also be fused or unfused with one or more cyclic hydrocarbon, heteroaryl, or heterocyclic rings.
- Heteroaryl is an aryl group containing from one to four heteroatoms, preferably N, O, or S, or a combination thereof, which heteroaryl group is optionally substituted at carbon or nitrogen atom(s) with Cl-6 alkyl, -CF3, phenyl, benzyl, or thienyl, or a carbon atom in the heteroaryl group together with an oxygen atom form a carbonyl group, or which heteroaryl group is optionally fused with a phenyl ring.
- Heteroaryl rings may also be fused with one or more cyclic hydrocarbon, heterocyclic, aryl, or heteroaryl rings.
- Heteroaryl includes, but is not limited to, 5- membered heteroaryls having one hetero atom (e.g., thiophenes, pyrroles, furans); 5- membered heteroaryls having two heteroatoms in 1,2 or 1,3 positions (e.g., oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-membered heteroaryls having three heteroatoms (e.g., triazoles, thiadiazoles); 5-membered heteroaryls having 3 heteroatoms; 6-membered heteroaryls with one heteroatom (e.g., pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine); 6-membered heteroaryls with two heteroatoms (e.g., pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines); 6-membered heteroary
- Heterocycle or “heterocyclic” means one or more rings of 5-12 atoms, preferably 5-7 atoms, with or without unsaturation or aromatic character and at least one ring atom which is not carbon. Preferred heteroatoms include sulfur, oxygen, and nitrogen. Multiple rings may be fused, as in quinoline or benzofuran.
- Heteroatom means any non-carbon atom in a hydrocarbon analog compound. Examples include oxygen, sulfur, nitrogen, phosphorus, arsenic, silicon, selenium, tellurium, tin, and boron.
- biologically active molecules when used herein means any substance which can affect any physical or biochemical properties of a biological organism, including but not limited to viruses, bacteria, fungi, plants, animals, and humans.
- biologically active molecules include any substance intended for diagnosis, cure mitigation, treatment, or prevention of disease in humans or other animals, or to otherwise enhance physical or mental well-being of humans or animals.
- biologically active molecules include, but are not limited to, peptides, proteins, enzymes, small molecule drugs, dyes, lipids, nucleosides, oligonucleotides, polynucleotides, nucleic acids, cells, viruses, liposomes, microparticles and micelles.
- Classes of biologically active agents that are suitable for use with the invention include, but are not limited to, antibiotics, fungicides, anti-viral agents, anti- inflammatory agents, anti-tumor agents, cardiovascular agents, anti-anxiety agents, hormones, growth factors, steroidal agents, and the like.
- Polyolefmic alcohol refers to a polymer comprising a polyolefm backbone, such as polyethylene, having multiple pendant hydroxyl groups attached to the polymer backbone.
- An exemplary polyolefmic alcohol is polyvinyl alcohol.
- non-peptidic refers to a polymer backbone substantially free of peptide linkages.
- the polymer backbone may include a minor number of peptide linkages spaced along the length of the backbone, such as, for example, no more than about 1 peptide linkage per about 50 monomer units.
- residue is meant the portion of a molecule remaining after reaction with one or more molecules.
- a biologically active molecule residue in a branched polymer conjugate of the invention is the portion of a biologically active molecule remaining following covalent linkage to a branched polymer of the invention.
- Oligomer refers to short monomer chains comprising 2 to about 10 monomer units, preferably 2 to about 5 monomer units.
- conjugate is intended to refer to the entity formed as a result of covalent attachment of a molecule, e.g., a biologically active molecule, to a reactive polymer molecule, preferably a branched reactive polymer of the invention.
- “Monofunctional” in the context of a polymer of the invention refers to a polymer possessing a single reactive functional group.
- “Bifunctional” in the context of a polymer of the invention refers to a polymer possessing two reactive functional groups which may be the same or different.
- “Multifunctional” in the context of a polymer of the invention means a polymer having 3 or more functional groups attached thereto, where the functional groups may be the same or different.
- Multifunctional polymers of the invention will typically comprise from about 3-100 functional groups, or from 3-50 functional groups, or from 3-25 functional groups, or from 3-15 functional groups, or from 3 to 10 functional groups, or will contain 3, 4, 5, 6, 7, 8, 9 or 10 functional groups attached to the polymer backbone.
- the present invention provides branched reactive polymers comprising at least two polymer arms, such as PEG arms, attached to a central core through heteroatom linkages such as ether linkages.
- the central core molecule is an aliphatic hydrocarbon having a carbon chain length of at least three carbon atoms (i.e., propane, butane, pentane, and the like). Since the branched polymers of the invention combine at least two polymer arms in a single molecule, a polymer with sufficient molecular weight to impart beneficial properties to a biologically active molecule, such as increased water solubility, can be formed " using shorter, easier to prepare polymer chains.
- the branched polymers of the invention are preferably monofunctional, meaning the polymer molecule contains only a single reactive site for conjugation to a biologically active molecule.
- Use of a monofunctional polymer eliminates the possibility of crosslinking with a biologically active molecule, such as a protein, which can lead to loss of activity.
- the branched polymers of the invention comprising poly(alkylene glycol) polymer arms, such as PEG arms
- the branched polymers are advantageously synthesized by polymerizing alkylene oxide monomer units, such as ethylene oxide units, directly onto an aliphatic hydrocarbon core molecule substituted with two or more nucleophilic groups (e.g., thiol, amino or hydroxyl groups).
- nucleophilic groups e.g., thiol, amino or hydroxyl groups.
- the total number average molecular weight of the branched reactive polymers of the invention will be about 500 to about 100,000 daltons (Da), preferably about 5,000 to about 60,000 Da, most preferably about 8,000 to about 40,000 Da.
- Each polymer arm of the branched polymer will typically have a molecular weight of about 250 Da to about 50,000 Da, more preferably about 2,500 to about 30,000 Da, and most preferably about 4,000 to about 20,000 Da.
- Branched polymers having a total number average molecular weight of about 500 Da, about 1,000 Da, about 2,000 Da, about 4,000 Da, about 5,000 Da, about 8,000 Da, about 10,000 Da, about 12,000 Da, about 15,000 Da, about 20,000, about 25,000 Da, and about 30,000 Da are particularly preferred.
- a branched reactive polymer of the invention will typically comprise at least two water-soluble and non-peptidic polymer arms, such as poly(ethylene glycol) arms, covalently attached to an aliphatic hydrocarbon core structure bearing a single functional group.
- a generalized structure of the branched reactive polymers of the invention is shown below:
- R is an aliphatic hydrocarbon having a length of at least three carbon atoms; each POLY is a water soluble and non-peptidic polymer, such as PEG; X' is a heteroatom linkage, preferably -NH-, -O-, or -S-; X is a linker; p is 0 or 1 ; q is 2 to about 10, preferably 2 to about 5 (e.g., 2, 3, 4, or 5); and
- Y is a functional group.
- the aliphatic hydrocarbon core, R preferably comprises 3 to about 12 carbon atoms, more preferably 3 to about 7 carbon atoms, most preferably 3 to about 5 carbon atoms. Core structures of 3, 4, and 5 carbon atoms in length are particularly preferred.
- the aliphatic hydrocarbon can be linear or branched and may include one or more heteroatoms in the hydrocarbon chain.
- the polymer arms, POLY, and the functional group, Y are each attached to different carbon atoms of the core molecule.
- the POLY polymer arms are preferably attached at the 1- and 3 -position and the Y functional group is preferably attached at the 2-position.
- the branched polymers of the invention are preferably symmetrical, meaning the polymer arms are symmetrically located on the central core, R (e.g., at the 1- and 3- position of a three-carbon aliphatic core).
- R e.g., at the 1- and 3- position of a three-carbon aliphatic core.
- the water soluble and non-peptidic polymer portion of the branched polymer structure should be non-toxic and biocompatible, meaning that the polymer is capable of coexistence with living tissues or organisms without causing harm.
- the polymer can be any of a number of water soluble and non-peptidic polymers, such as those described herein as suitable for use in the present invention.
- POLY as designated in Formula I above is poly(ethylene glycol) (PEG).
- PEG includes polyethylene glycol in any of a number of geometries or forms, including linear forms (e.g., alkoxy PEG or bifunctional PEG), branched or multi-arm forms (e.g., forked PEG or PEG attached to a polyol core), pendant PEG, or PEG with degradable linkages therein, to be more fully described below.
- linear forms e.g., alkoxy PEG or bifunctional PEG
- branched or multi-arm forms e.g., forked PEG or PEG attached to a polyol core
- pendant PEG e.g., forked PEG or PEG attached to a polyol core
- PEG with degradable linkages therein
- End-capped polymers meaning polymers having at least one terminus capped with a relatively inert group (e.g., an alkoxy group), can be used as a polymer of the invention.
- a relatively inert group e.g., an alkoxy group
- methoxy-PEG-OH, or mPEG in brief is a form of PEG wherein one terminus of the polymer is a methoxy group, while the other terminus is a hydroxyl group that is subject to ready chemical modification.
- the structure of mPEG is given below.
- Multi-armed or branched PEG molecules such as those described in U.S. Patent No. 5,932,462, which is incorporated by reference herein in its entirety, although less preferred, can also be used as the PEG polymer in the branched reactive polymers of the invention.
- an exemplary branched PEG polymer can have the structure: POlVa P
- poly a and poly b are PEG backbones, such as methoxy poly(ethylene glycol);
- R" is a nonreactive moiety, such as H, methyl or a PEG backbone; and P and Q are nonreactive linkages.
- the branched PEG polymer is methoxy poly(ethylene glycol) disubstituted lysine.
- use of branched polymers as the POLY polymer arms in the branched reactive polymers of the invention would result in a polymer having multiple branching points within the molecule.
- Such polymers if utilized to prepare the branched structures of the invention, are attached to the aliphatic core structures provided herein not by polymerization but by covalent attachment.
- the PEG polymer may alternatively comprise a forked PEG.
- a polymer having a forked structure is characterized as having a polymer chain attached to two or more active agents via covalent linkages extending from a hydrolytically stable branch point in the polymer.
- An example of a forked PEG is represented by -PEG-YCHZ 2 , where Y is a linking group and each Z is an activated terminal group for covalent attachment to a biologically active agent. The Z group is linked to CH by a chain of atoms of defined length.
- the chain of atoms linking the Z functional groups to the branching carbon atom serve as a tethering group and may comprise, for example, an alkyl chain, ether linkage, ester linkage, amide linkage, or combinations thereof.
- the resulting branched polymer is multifunctional, i.e., having reactive sites suitable for attachment to a biologically active molecule not only extending from the aliphatic core, but also extending from the forked polymer arm(s).
- such forked polymers if utilized to prepare the branched structures of the invention, are attached to the aliphatic core structures provided herein not by polymerization but typically by covalent attachment.
- the PEG polymer may comprise a pendant PEG molecule having reactive groups, such as carboxyl, covalently attached along the length of the PEG backbone rather than at the end of the PEG chain.
- the pendant reactive groups can be attached to the PEG backbone directly or through a linking moiety, such as an alkylene group.
- the polymer arms can also be prepared with one or more weak or degradable linkages in the polymer backbone, including any of the above described polymers.
- PEG can be prepared with ester linkages in the polymer backbone that are subject to hydrolysis. As shown below, this hydrolysis results in cleavage of the polymer into fragments of lower molecular weight:
- hydrolytically degradable linkages useful as a degradable linkage within a polymer backbone, include carbonate linkages; imine linkages resulting, for example, from reaction of an amine and an aldehyde (see, e.g., Ouchi et al., Polymer Preprints, 38(l):582-3 (1997), which is incorporated herein by reference.); phosphate ester linkages formed, for example, by reacting an alcohol with a phosphate group; hydrazone linkages which are typically formed by reaction of a hydrazide and an aldehyde; acetal linkages that are typically formed by reaction between an aldehyde and an alcohol; ortho ester linkages that are, for example, formed by reaction between a formate and an alcohol; peptide linkages formed by an amine group, e.g., at an end of a poly
- the polymer arms having one or more hydrolyzable linkages contained therein are prepared in a two-step polymerization process which includes an intermediate step for inclusion of the desired hydrolyzable linkage. That is to say, polymerization of, e.g., ethylene oxide subunits, onto the central core is carried out to a certain desired chain length and the reactive polymer termini extending from the central core are then coupled to short polymer chains suitably functionalized at one end to react with the hydroxyl groups of the intermediate polymer arms extending from the core to introduce the hydrolyzable linkage(s). Further polymerization of ethylene oxide subunits onto the polymer arms, now containing one or more hydrolyzable linkages, is then carried out to prepare polymer arms of a desired chain length.
- polymerization of, e.g., ethylene oxide subunits, onto the central core is carried out to a certain desired chain length and the reactive polymer termini extending from the central core are then coupled to short polymer chains suitably functionalized at one end to react with the
- poly(ethylene glycol) or PEG represents or includes all the above forms of PEG.
- the polymer backbone can be linear, or can be in any of the above-described forms (e.g., branched, forked, and the like).
- suitable polymers include, but are not limited to, other poly(alkylene glycols), copolymers of ethylene glycol and propylene glycol, poly(olefmic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly( ⁇ -hydroxy acid), poly(acrylic acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N- acryloylmorpholine), such as described in U.S. Patent No. 5,629,384, which is incorporated by reference herein in its entirety, and copolymers, terpolymers, and mixtures thereof.
- the two or more polymer arms of a branched polymer of the invention are the same. That is to say, most preferably, the polymer arms are each a poly(ethylene glycol) or each a polyolefmic alcohol, etc. Generally, not only are the polymer arms composed of the same type of subunits, but they also have identical geometries and similar molecular weights. That is to say, in a most preferred embodiment of the invention, the polymer arms extending from the aliphatic core are identical.
- the branched polymers of the invention optionally include a linkage (i.e., X in Formula I) that joins a branching carbon of the aliphatic hydrocarbon central core molecule with the functional group, Y.
- the structure of the X linkage is typically determined by the structure of the aliphatic hydrocarbon core used to form the polymers of the invention and has an overall length of from 1 to about 40 atoms, preferably 1 to about 10 atoms, and most preferably 1 to about 5 atoms.
- Preferred linkages include heteroatoms such as -O- or -S-, -alkylene-, -O-alkylene-O-, - alkylene-O-alkylene-, -aryl-O- (e.g., -phenylene-O-), -O-aryl- (e.g., -O-phenylene), (- O-alkylene-) m , and (-alkylene-O-) m , wherein m is 1-10, preferably 1-5 (e.g., 1, 2, 3, 4, or 5).
- the alkylene groups of the X linkage are preferably Cl-C6alkylene, more preferably C1-C3 alkylene, including methylene and ethylene.
- a linker i.e., X in Formula I
- the terminus for activation and subsequent attachment to an active agent is then at a primary rather than at a secondary carbon position, thereby increasing the ease of subsequent modifications due to the increased reactivity of a primary carbon in nucleophilic displacement reactions.
- the Y functional group can be any functional group suitable for reaction with a functional group on a biologically active molecule or a functional group that is a precursor thereof
- suitable functional groups include hydroxyl, active ester (e.g., N-hydroxysuccinimidyl ester and 1-benzotriazolyl ester), active carbonate (e.g., N-hydroxysuccinimidyl carbonate, 1-benzotriazolyl carbonate, p-nitrophenyl carbonate), acetal, aldehyde having a carbon length of 1 to 25 carbons (e.g., acetaldehyde, propionaldehyde, and butyraldehyde), aldehyde hydrate, alkenyl, acrylate, methacrylate, acrylamide, active sulfone, amine, hydrazide, thiol, alkanoic acids having a carbon length (including the carbonyl carbon) of 1 to about 25 carbon atoms (e.g., carboxylic
- N-succinimidyl carbonate see e.g., U.S. Patent Nos. 5,281,698, 5,468,478,
- amine see, e.g., Buckmann et al. Makromol.Chem. 182:1379 (1981), Zalipsky et al. Eur. Polym. J. 19:1177 (1983)
- hydrazide See, e.g., Andresz et al. Makromol. Chem. 179:301 (1978)
- succinimidyl propionate and succinimidyl butanoate see, e.g., Olson et al.
- succinimidyl succinate See, e.g., Abuchowski et al. Cancer Biochem. Biophys. 7:175 (1984) and Joppich et al., Makromol. Chem. 180:1381 (1979), succinimidyl ester (see, e.g., U.S. Patent No. 4,670,417), benzotriazole carbonate (see, e.g., U.S. Patent No.
- glycidyl ether see, e.g., Pitha et al. Eur. J. Biochem. 94:11 (1979), Elling et al., Biotech. Appl. Biochem. 13:354 (1991), oxycarbonylimidazole (see, e.g., Beauchamp, et al., Anal. Biochem. 131:25 (1983), Tondelli et al. J. Controlled Release 1:251 (1985)), p- nitrophenyl carbonate (see, e.g., Veronese, et al., Appl. Biochem. Biotech., 11:141 (1985); and Sartore et al., Appl. Biochem.
- the Y functional group is a protected functional group, such as a protected hydroxyl group of formula -O-Gp, wherein Gp is a protecting group.
- the Gp protecting group can be any of various hydroxyl protecting groups known in the art, such as benzyl or other alkylaryl groups (e.g., groups having the formula -CH 2 -Ar, wherein Ar is any aryl group), acetal, and dihydropyranyl.
- Other suitable protecting groups are described in Greene, T.W., et al, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 3rd ed., John Wiley & Sons, New York, NY (1999).
- the protecting group, Gp can be readily displaced from the molecule to form a hydroxyl group, which can be further modified to form other functional groups using techniques known in the art.
- the branched polymers of the invention are composed of an aliphatic hydrocarbon-based core (i.e., R in Formula I above) having a length of least three carbon atoms, preferably from 3 to 7 carbon atoms. That is to say, a central core structure will typically contain at its core a number of carbon atoms selected from the following: 3, 4, 5, 6, 7 or more carbon atoms. Preferred are core structures containing 3, 5 or 7 core carbons. Although the carbon atoms of the central core may have polymer arms extending from any of the aforementioned carbons, preferably but not necessarily, the overall branched polymer is symmetrical.
- the polymer arms preferably extend from positions 1 and 3, with a site suitable for covalent attachment to a biologically active molecule extending from the central carbon or the carbon at position 2.
- the polymer arms extend from positions 1 and 5, with a site suitable for covalent attachment to a biologically active molecule extending from position 3, or polymer arms extending from positions 2 and 4, or, if a highly branched structure is desired, with polymer arms extending from each of positions 1, 2, 4, and 5.
- Exemplary three- carbon core structures possessing as the nucleophile an oxygen atom directly attached to carbons 1 and 3 are provided in the Examples. These examples demonstrate synthetic approaches for building core structures having a variety of (X)p groups.
- the nucleophiles (heteroatoms) attached to the central core are the same, e.g., all oxygen, all nitrogen, etc.
- suitable for use in forming the branched polymers of the invention are unsymmetrical core structures such as those derived from 2- aminopentanedioic acid (glutamic acid), 2-aminosuccinic acid (aspartic acid), and the like.
- the terminal acid groups are typically activated for coupling with a reactive polymer to form the branched polymer core.
- the carboxylic acid groups are reduced with a reducing agent to form the corresponding diol, which then possesses sites suitable for building the polymer chains, for example, by a catalyzed reaction of the N-protected diol with an appropriate monomer subunit and subsequent polymerization thereof directly onto the central core.
- One embodiment of the invention having a three-carbon core has the structure: POLY-O-CH 2
- the branched polymer of the invention has the structure:
- Z is a capping group or a functional group; and POLY, X, p, and Y are described above.
- the Z group is preferably a relatively inert capping group, such as alkoxy (e.g. methoxy or ethoxy), alkyl, benzyl, aryl, or aryloxy (e.g. benzyloxy).
- the Z group is a functional group capable of readily reacting with a functional group on a biologically active molecule, such as any of the functional groups discussed above for the Y functional group.
- each POLY is PEG end-capped with methoxy as shown below:
- Formula Ia 3 wherein: Z, POLY, and Y are defined above.
- Z is methoxy and POLY is PEG.
- the X linkage is one of the specific linkages shown below:
- X is -CH 2 CH 2 -O-CH 2 CH 2 - or -O-CH 2 CH 2 -;
- Z, POLY and Y are defined above.
- Z is methoxy and POLY is PEG.
- heteroatoms such as -NH- or -S- could be used in place of the -O- linkages illustrated in Formulas la, Iaj, Ia , Ia 3 , and Ia-t above.
- branched Reactive Polymers are formed by attaching polymer arms to a heteroatom-substituted aliphatic hydrocarbon core molecule having at least three carbon atoms, such as propane, via heteroatom linkages (e.g., -NH-, -O- or -S-).
- a heteroatom-substituted aliphatic hydrocarbon core molecule having at least three carbon atoms, such as propane, via heteroatom linkages (e.g., -NH-, -O- or -S-).
- poly(alkylene glycol) polymers it is preferable in many respects to directly polymerize alkylene oxide monomer units, such as ethylene oxide, propylene oxide, or butylene oxide subunits, onto an aliphatic hydrocarbon core bearing at least two available hydroxyl groups (or other nucleophilic groups such as amino or thiol groups).
- alkylene oxide monomer units such as ethylene oxide, propylene oxide, or butylene oxide subunits
- alkylene oxide units can be polymerized onto, for example, an alcohol molecule using a catalyzed reaction to form ether-linked polymer arms, preferably using base catalysis although other catalysts such as metal or acid catalysts could also be employed.
- a catalyzed reaction to form ether-linked polymer arms
- other catalysts such as metal or acid catalysts could also be employed.
- the branched polymer can be formed without first forming and purifying high molecular weight polymers, which is technically challenging, expensive, and time-consuming.
- the aliphatic hydrocarbon core molecule comprises two or more available nucleophilic groups, such as hydroxyl groups, depending on the number of polymer arms to be attached to the core molecule.
- the aliphatic hydrocarbon has two hydroxyl groups.
- the core molecule also bears at least one protected functional group, such as a protected hydroxyl group (i.e., -O-Gp, where Gp is described above).
- the aliphatic hydrocarbon is l,3-dihydroxy-2- substituted propane, wherein the protected hydroxyl group is attached at the 2- position, optionally via an intervening linkage (i.e., X in Formula I above).
- the presence of the protecting group prevents polymerization at that position, thereby ensuring that at least one side chain of the aliphatic hydrocarbon core will be available for further modification, for example, to a form suitable for covalent attachment to a biologically active molecule.
- Y' is a protected functional group, such as a protected hydroxyl group, wherein the presence of the protecting group prevents polymerization at the Y' position on the aliphatic core, R;
- Nu is a nucleophile, such as amino, thiol or hydroxyl; and R, X, p and q are defined above.
- the present invention utilizes a nucleophile-substituted aliphatic hydrocarbon core molecule to form a branched polymer suitable for covalent coupling to a biologically active molecule.
- X, p, and Gp are defined above.
- Exemplary core structures of Formula Va include 2 -benzyloxy- 1,3- propanediol, 2-benzyloxyethoxy- 1,3-propanediol, and 2-benzyloxyethoxyethyl-l,3- propanediol.
- the core structures of Formula V are either commercially available (See Examples 1-2) or can be prepared from commercially available reagents (See Examples 3-4).
- Base-initiated polymerization of ethylene oxide onto a hydroxyl-substituted aliphatic hydrocarbon of Formula Va results in a branched polymer of Formula la where Y is -O-Gp and POLY is -PEG-OH.
- the terminal hydroxyl groups of the PEG polymer chains are preferably alkylated (e.g., methylated to form mPEG) by reaction with an alkylating agent, such as methyl toluenesulfonate.
- the protecting group, Gp can be displaced by hydrolysis or hydrogenolysis to produce a hydroxyl group.
- the hydroxyl group can then be modified or converted to other reactive groups as desired, such as the reactive groups listed above for the Y moiety of Formula I.
- the present invention also includes biologically active conjugates comprising a biologically active molecule covalently attached to a branched polymer of the invention.
- the branched polymers of the invention are preferably although not necessarily monofunctional (e.g., they may also be bifunctional or less preferably multifunctional), and the biologically active agent is preferably attached to the branched polymer via a linkage formed from reaction of the functional group on the branched polymer and a functional group on the biologically active agent.
- an amide linkage can be formed by reaction of a branched polymer bearing a carboxylic acid group, or an active ester thereof, in the presence of a coupling agent, such as DCC, DMAP, or HOBT, with a biologically active agent having an amine group.
- a coupling agent such as DCC, DMAP, or HOBT
- a sulfide linkage can be formed by reaction of a branched polymer bearing a thiol group with a biologically active agent bearing a hydroxyl group.
- an amine linkage is formed by reaction of a branched polymer bearing an amino group with a biologically active molecule bearing a hydroxyl group.
- a branched polymer bearing a carboxylic acid is reacted with a biologically active molecule bearing a hydroxyl group in the presence of a coupling agent to form an ester linkage.
- the particular coupling chemistry employed will depend upon the structure of the biologically active agent, the potential presence of multiple functional groups within the biologically active molecule, the need for protection/deprotection steps, chemical stability of the molecule, and the like, and will be readily determined by one skilled in the art.
- Illustrative linking chemistry useful for preparing the branched polymer conjugates of the invention can be found, for example, in Wong, S.H., (1991), “Chemistry of Protein Conjugation and Crosslinking", CRC Press, Boca Raton, FL and in Brinkley, M. (1992) "A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Crosslinking Reagents ", in Bioconjug. Chem., 3, 2013.
- the linkage (i.e., Lj in Formula VI below) can be hydrolytically degradable so that the biologically active agent is released into circulation over time after administration to a patient.
- exemplary hydrolytically degradable linkages include carboxylate ester, phosphate ester, anhydrides, acetals, ketals, acyloxyalkyl ether, imines, orthoesters, peptides and oligonucleotides.
- a hydrolytically stable linkage such as amide, urethane (also known as carbamate), amine, thioether (also known as sulfide), and urea (also known as carbamide) linkages, can also be used without departing from the invention.
- a generalized structure for a biologically active conjugate of the invention comprising a branched polymer of Formula I can be represented as shown below:
- D is a biologically active molecule, such as a peptide, protein, enzyme, small molecule drug, dye, lipid, nucleoside, nucleotide, oligonucleotide, polynucleotide, nucleic acid, polysaccharide, steroid, cell, virus, liposome, microparticle, micelle, fat, electrolyte and the like;
- Lj is a linkage resulting from the reaction of the functional group of the branched polymer (i.e., Y in Formula I) and a functional group on the biologically active molecule;
- the biologically active conjugate has the structure:
- a biologically active agent for use in coupling to a branched polymer of the invention may be any one or more of the following.
- Suitable agents may be selected from, for example, hypnotics and sedatives, psychic energizers, tranquilizers, respiratory drugs, anticonvulsants, muscle relaxants, antiparkinson agents (dopamine antagnonists), analgesics, anti-inflammatories, antianxiety drugs (anxiolytics), appetite suppressants, antimigraine agents, muscle contractants, anti-infectives (antibiotics, antivirals, antifungals, vaccines) antiarthritics, antimalarials, antiemetics, anepileptics, bronchodilators, cytokines, growth factors, anti-cancer agents, antithrombotic agents, antihypertensives, cardiovascular drugs, antiarrhythmics, antioxicants, anti-asthma agents, hormonal agents including contraceptives, sympathomimetics, diuretics,
- active agents suitable for use in covalent attachment to a branched polymer of the invention include, but are not limited to, calcitonin, erythropoietin (EPO), Factor VIII, Factor IX, ceredase, cerezyme, cyclosporin, granulocyte colony stimulating factor (GCSF), thrombopoietin (TPO), alpha- 1 proteinase inhibitor, elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth hormone, human growth hormone (HGH), growth hormone releasing hormone (GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin-1 receptor, interleukin-2, interleukin-1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, luteinizing hormone releasing hormone (LHRH), factor IX insulin, pro- insulin, insulin analogues (e
- Patent No. 5,922,675 amylin, C-peptide, somatostatin, somatostatin analogs including octreotide, vasopressin, follicle stimulating hormone (FSH), insulin-like growth factor (IGF), insulintropin, macrophage colony stimulating factor (M-CSF), nerve growth factor (NGF), tissue growth factors, keratinocyte growth factor (KGF), glial growth factor (GGF), tumor necrosis factor (TNF), endothelial growth factors, parathyroid hormone (PTH), glucagon-like peptide thymosin alpha 1, Ilb/IIIa inhibitor, alpha- 1 antitrypsin, phosphodiesterase (PDE) compounds, VLA-4 inhibitors, bisphosphonates, respiratory syncytial virus antibody, cystic fibrosis transmembrane regulator (CFTR) gene, deoxyreibonuclease (Dnase), bactericidal/permeability increasing protein (BPI), anti-
- Examples 1-2 illustrate a method of forming a branched reactive polymer of the invention using a commercially available hydroxyl-substituted aliphatic hydrocarbon core molecule (2 -benzyloxy- 1,3-propanediol).
- the branched polymer is functionalized with an acetaldehyde diethyl acetal.
- the branched polymer is functionalized with a succinimidyl ester of butyric acid.
- Examples 3-4 illustrate a method of synthesizing two additional core molecules having intervening linkages between the aliphatic hydrocarbon core molecule and the protected hydroxyl side chain.
- Examples 5-6 illustrate PEGylation of an enzyme with a branched polymer of the invention to form a conjugate.
- Example 1 Synthesis of 2-( 3-di-mPEGoxy-2-propanoxy acetaldehyde diethyl acetal
- a 500 ml round bottom flask was charged with 250 ml of freshly distilled, dry THF containing 2-benzyloxy-l,3-propanediol (.84g, 4.59 mmole). Potassium naphthalenide was added (0.28 M, 16.4 ml) with continuous stirring under an inert atmosphere. The flask was then cooled to 0°C in an ice bath. Ethylene oxide (50.0 ml, 1.02 moles) was added via a cooled syringe. The reaction was allowed to warm to room temperature and was stirred for 72 hours. The reaction was quenched by the addition of 5 ml of .2M acetic acid.
- the solvents were removed by rotary evaporation and the crude material redissolved in 100 ml of methylene chloride.
- the product was precipitated by the addition of 400 ml of diethyl ether and collected by filtration. The product was dried under vacuum.
- Methyl toluenesulfonate (0.81 ml) and 1.4 ml of potassium t-butoxide solution were then added and the reaction was stirred for an additional 3 hours.
- the flask was removed from the oil bath and cooled to room temperature.
- the solution was transferred to a single-necked round bottom flask and the solvent was removed by rotary evaporation.
- the residue was dissolved in 5 ml of methylene chloride and precipitated by the addition of 50 ml of diethyl ether.
- the product was collected by filtration and dried under vacuum.
- the suspension was filtered to remove catalyst and the filtrate was saturated with NaCl and the pH of the solution was adjusted to 3.0.
- the solution was extracted with dichloromethane (300 ml x 2) and the combined extracts were dried over Na 2 SO 4 , filtered, evaporated and precipitated with Et 2 O ( 500 mL). The product was collected by vacuum filtration and dried in vacuum overnight.
- the solvent was evaporated to dryness under reduced pressure, the residue dried under vacuum for 2 hours, and finally redissolved in 60 ml of deionized water.
- the pH of the solution was adjusted to 2.0 with 10 % H 3 PO 4 .
- the pH of the solution was adjusted to 12.0 with 1.0 N NaOH and stirred at pH 12.0 for 2 hours.
- the hydrolyzed solution was saturated with NaCl and the pH adjusted to 3.0 with 10% H 3 PO 4 .
- the solution was extracted with dichloromethane (100 ml x 2) and the combined extracts were dried over Na SO 4 , filtered, evaporated and precipitated with Et O (100 mL).
- the product was collected by vacuum filtration and dried in vacuum overnight. Yield: 2.3 g GPC: 79 %.
- the crude 2-(l,3-di-mPEGoxy-2-propanoxy) butyric acid from Step C was purified by DEAE sepharose FF ion exchange column (100 mL). After purification, the yield was 1.55 g. 1H nmr ( DMSO-d6): ⁇ 3.5ppm ( br.muk., PEG), ⁇ 3.24 ppm( s, CH 3 OPEG-), ⁇ 2.23 ppm( t, -OC ⁇ CHzCH ⁇ COOH), ⁇ 1.70 ppm ( mult. -OCH 2 CH 2 CH 2 COOH ).
- the remaining diethyl malonate was distilled off under reduced pressure. After distillation, the residue was purified by flash chromatography on a silica gel column eluted with hexane followed by dichloromethane. The combined dichloromethane extracts were evaporated to dryness and the product dried under vacuum overnight.
- Lysozyme (0.002 lg, Sigma) was dissolved in 1 ml of 50 mM sodium phosphate buffer (pH 7.5) in a 2ml vial.
- MPEG2 (20 kDa)-SBA (0.006g, 2 fold molar excess to the lysozyme) from Example 2 was added and the reaction vial was shaken at room temperature for 18 h.
- the MALDI-TOF spectrum of the crude reaction mixture showed lysozyme
- PAGE (10% Tris-HCL gel) displayed six bands indicating tetra-, tri-, di-, mono- pegylated lysozyme (meaning polymer-modified forms of the enzyme having 4, 3, 2, and 1 of the branched polymers of the invention covalently attached thereto, respectively), PEG2 (20K)-butanoic acid, and unpegylated lysozyme.
- Example 5 demonstrates the utility of the polymers of the invention in forming conjugates having an amide linkage coupling the branched polymer structure with a biological agent.
- lysozyme 2.2mg, 1.9mg, and 2Jmg of lysozyme (Sigma) were dissolved in 1 ml of 50 mM sodium phosphate buffer of pH 5.5, 6.5, and 7.6, respectively.
- 1.5 mg of di- mPEG 2kDa-butyraldehyde (5 fold molar excess relative to the lysozyme) and 0J mg of NaCNBH (10 fold molar excess relative to the lysozyme) were added to the lysozyme solution of pH 5.5.
- Example 6 demonstrates the utility of the polymers of the invention in forming conjugates wherein a biologically active agent is covalently coupled to the branched polymer via a secondary amine linkage generated by reductive amination of the corresponding Schiff base.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02789492A EP1446438A2 (en) | 2001-11-07 | 2002-11-07 | Branched polymers and their conjugates |
MXPA04004336A MXPA04004336A (es) | 2001-11-07 | 2002-11-07 | Polimeros ramificados y sus conjugados. |
AU2002352524A AU2002352524B2 (en) | 2001-11-07 | 2002-11-07 | Branched polymers and their conjugates |
CA2466027A CA2466027C (en) | 2001-11-07 | 2002-11-07 | Branched polymers and their conjugates |
JP2003542253A JP4758608B2 (ja) | 2001-11-07 | 2002-11-07 | 分枝ポリマーおよびそれらの結合体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33761301P | 2001-11-07 | 2001-11-07 | |
US60/337,613 | 2001-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003040211A2 true WO2003040211A2 (en) | 2003-05-15 |
WO2003040211A3 WO2003040211A3 (en) | 2003-07-03 |
Family
ID=23321254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/035759 WO2003040211A2 (en) | 2001-11-07 | 2002-11-07 | Branched polymers and their conjugates |
Country Status (8)
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022630A2 (en) * | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
WO2005000941A1 (en) * | 2003-06-05 | 2005-01-06 | Dow Global Technologies, Inc. | Novel polymer compositions |
EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
WO2005108463A2 (en) * | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
WO2006005058A2 (en) * | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
WO2006019950A2 (en) * | 2004-07-16 | 2006-02-23 | Nektar Therapeutics Al, Corporation | Conjugates of a gm-csf moiety and a polymer |
JP2007501812A (ja) * | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
WO2007062610A3 (es) * | 2005-11-30 | 2007-09-20 | Ct Ingenieria Genetica Biotech | Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos |
US7273845B2 (en) | 2002-11-12 | 2007-09-25 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
US7462687B2 (en) | 2002-11-12 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkages |
WO2010121559A1 (zh) | 2009-04-23 | 2010-10-28 | 派格生物医药(苏州)有限公司 | 新型exendin变体及其缀合物 |
US7884075B2 (en) | 2004-12-27 | 2011-02-08 | Baxter International Inc. | Polymer-factor VIII-von Willebrand factor-conjugates |
EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
WO2012029038A1 (de) | 2010-09-01 | 2012-03-08 | Basf Se | Amphiphil zur solubilisierung schwerlöslicher wirkstoffe |
US8273833B2 (en) | 2001-11-07 | 2012-09-25 | Nektar Therapeutics | Branched Polymers |
US8436104B2 (en) | 2003-06-20 | 2013-05-07 | Warwick Effect Polymers Limited | Polymer |
US8449714B2 (en) | 2005-12-08 | 2013-05-28 | Covidien Lp | Biocompatible surgical compositions |
CN104109238A (zh) * | 2014-07-13 | 2014-10-22 | 成都市绿科华通科技有限公司 | 六方孔状功能聚乙二醇的制备方法 |
EP2896642A1 (en) * | 2014-01-16 | 2015-07-22 | Shin-Etsu Chemical Co., Ltd. | Method for producing polyalkylene glycol derivative with narrow molecular weight distribution, and acetal-group containing alcohol compound for use therein and alkali metal salt thereof |
US9187404B2 (en) | 2014-01-16 | 2015-11-17 | Shin-Etsu Chemical Co., Ltd. | Method for producing polyalkylene glycol derivative having amino group at end, with narrow molecular weight distribution |
EP2947111A4 (en) * | 2013-01-17 | 2016-01-13 | Xiamen Sinopeg Biotech Co Ltd | Mono-functional Branched Polyethylene Glycol and Modified Biological Substance |
EP2586811A4 (en) * | 2010-06-25 | 2016-10-19 | Nof Corp | HIERÉRO-POLYETHYLENE GLYCOL BRANCHED AND INTERMEDIATE |
US10040761B2 (en) | 2010-06-25 | 2018-08-07 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
WO2020063628A1 (zh) | 2018-09-26 | 2020-04-02 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc融合蛋白及其缀合物 |
WO2021000767A1 (zh) | 2019-07-02 | 2021-01-07 | 郑州晟斯生物科技有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
US11020458B2 (en) | 2006-03-31 | 2021-06-01 | Takeda Pharmaceutical Company Limited | Factor VIII polymer conjugates |
WO2022063885A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable anti-peg antibodies in a patient |
Families Citing this family (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2315526T3 (es) * | 2002-09-09 | 2009-04-01 | Nektar Therapeutics Al, Corporation | Metodo para preparar derivados polimericos solubles en agua que llevan un acido carboxilico terminal. |
GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
CA2517145C (en) * | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2005035727A2 (en) * | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Polymer derivatives |
JP5268255B2 (ja) * | 2003-11-21 | 2013-08-21 | エイエヌピー テクノロジーズ, インコーポレイテッド | 非対称分岐ポリマー抱合体およびマイクロアレイアッセイ |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
WO2006009901A2 (en) * | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
US7638299B2 (en) * | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
JP4920593B2 (ja) * | 2004-10-25 | 2012-04-18 | インテザイン テクノロジーズ, インコーポレイテッド | ヘテロ二官能性ポリ(エチレングリコール)およびそれらの使用 |
MX2007007591A (es) | 2004-12-22 | 2007-07-25 | Ambrx Inc | Metodos para expresion y purificacion de hormona de crecimiento humano recombinante. |
EP1836298B1 (en) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
ATE542920T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
MX2007007590A (es) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
WO2006102484A2 (en) * | 2005-03-21 | 2006-09-28 | Anp Technologies, Inc. | Symmetrically branched polymer conjugates and microarray assays |
US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
US8563329B2 (en) | 2005-05-02 | 2013-10-22 | Anp Technologies, Inc. | Polymer conjugate enhanced bioassays |
CN103030690A (zh) | 2005-06-03 | 2013-04-10 | Ambrx公司 | 经改良人类干扰素分子和其用途 |
EP2412744B1 (en) | 2005-07-18 | 2014-01-22 | Nektar Therapeutics | Method for preparing branched functionalised polymers using branched polyol cores |
JP2007112924A (ja) * | 2005-10-21 | 2007-05-10 | National Institute For Materials Science | 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体 |
US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
CN105384807A (zh) * | 2005-12-14 | 2016-03-09 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
JP5096363B2 (ja) * | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
US20100012883A1 (en) * | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Functional Polymeric Phase Change Materials |
US20070173154A1 (en) * | 2006-01-26 | 2007-07-26 | Outlast Technologies, Inc. | Coated articles formed of microcapsules with reactive functional groups |
US9234059B2 (en) * | 2008-07-16 | 2016-01-12 | Outlast Technologies, LLC | Articles containing functional polymeric phase change materials and methods of manufacturing the same |
US8404341B2 (en) | 2006-01-26 | 2013-03-26 | Outlast Technologies, LLC | Microcapsules and other containment structures for articles incorporating functional polymeric phase change materials |
US20100016513A1 (en) * | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Functional Polymeric Phase Change Materials and Methods of Manufacturing the Same |
JP5528710B2 (ja) * | 2006-02-28 | 2014-06-25 | オリガシス コーポレイション | アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法 |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
CA2650035C (en) | 2006-04-27 | 2015-02-03 | Intezyne Technologies, Inc. | Poly (ethylene glycol) containing chemically disparate endgroups |
EP2018437A2 (en) * | 2006-05-02 | 2009-01-28 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
US8232360B2 (en) | 2006-07-17 | 2012-07-31 | Research Foundation Of State University Of N.Y. | Stereoregular ROMP polymers |
AU2007292903B2 (en) | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
SG174781A1 (en) | 2006-09-08 | 2011-10-28 | Ambrx Inc | Hybrid suppressor trna for vertebrate cells |
US8367065B2 (en) * | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
CA2662973A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Lysine-based polymeric linkers |
CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
US20140011964A1 (en) * | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
BRPI0721948A2 (pt) * | 2007-08-20 | 2014-04-08 | Enzon Pharmaceuticals Inc | Ligantes poliméricos contendo frações dissulfeto de piridila |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
NZ584825A (en) | 2007-11-20 | 2013-03-28 | Ambrx Inc | Modified insulin polypeptides and their uses |
US9345809B2 (en) * | 2007-11-28 | 2016-05-24 | Fziomed, Inc. | Carboxymethylcellulose polyethylene glycol compositions for medical uses |
JP5702150B2 (ja) | 2008-02-08 | 2015-04-15 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾されているレプチンポリペプチドおよびそれらの使用 |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
MX2010010953A (es) * | 2008-04-03 | 2011-04-21 | Biosteed Gene Expression Tech Co Ltd | Hormona de crecimiento modificada con glicol de polietileno de doble cadena, metodo de preparacion y aplicación del a misma. |
AU2009236635B2 (en) | 2008-04-14 | 2014-02-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
US8476404B1 (en) * | 2008-07-04 | 2013-07-02 | Bhalchandra Shripad Lele | Selectively functionalized polyhydric compounds |
US20100015430A1 (en) * | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Heat Regulating Article With Moisture Enhanced Temperature Control |
US8221910B2 (en) | 2008-07-16 | 2012-07-17 | Outlast Technologies, LLC | Thermal regulating building materials and other construction components containing polymeric phase change materials |
JP5680534B2 (ja) | 2008-07-23 | 2015-03-04 | イーライ リリー アンド カンパニー | 修飾されているウシg−csfポリペプチドおよびそれらの使用 |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
WO2010033205A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
US20110171166A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
EP2344199A1 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
WO2010033221A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
US20110206633A1 (en) * | 2008-09-19 | 2011-08-25 | Nektar Therapectics | Polymer conjugates of cd-np peptides |
WO2010033215A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
EP2334337A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
WO2010033224A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
US20110171163A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of ziconotide peptides |
WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
WO2010033220A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
JP4966434B2 (ja) * | 2008-10-15 | 2012-07-04 | バクスター・インターナショナル・インコーポレイテッド | 結合抗体の存在下における組換え血液凝固因子のpeg化 |
CN102307993B (zh) | 2008-12-09 | 2014-06-25 | 哈洛齐梅公司 | 延长的可溶性ph20多肽及其用途 |
TW201042257A (en) * | 2009-05-26 | 2010-12-01 | Baxter Int | Detection of antibody that binds to water soluble polymer-modified polypeptides |
ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2774053C (en) | 2009-09-17 | 2015-04-28 | Baxter Healthcare, S.A. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
US20110081398A1 (en) * | 2009-10-01 | 2011-04-07 | Tyco Healthcare Group Lp | Multi-mechanism surgical compositions |
US8968785B2 (en) * | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
US20110081701A1 (en) * | 2009-10-02 | 2011-04-07 | Timothy Sargeant | Surgical compositions |
US8697648B2 (en) * | 2009-10-20 | 2014-04-15 | Georgia State University Research Foundation, Inc. | Protein agent for diabetes treatment and β cell imaging |
WO2011081915A2 (en) * | 2009-12-15 | 2011-07-07 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
CN107674121A (zh) | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
CN104017063A (zh) | 2009-12-21 | 2014-09-03 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
JP5914363B2 (ja) * | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー/エス | 低減されたvwf結合を有する因子viii分子 |
KR20130115086A (ko) | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
MX348420B (es) | 2010-07-20 | 2017-06-12 | Halozyme Inc | Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios. |
MX346271B (es) | 2010-07-30 | 2016-07-08 | Baxalta Inc | Catalizadores nucleofílicos para enlace de oxima. |
MX346786B (es) | 2010-08-17 | 2017-03-31 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos. |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US8841382B2 (en) | 2010-09-01 | 2014-09-23 | Basf Se | Hyperbranched polyethers/dendrimers for solubilzation of sparingly soluble active ingredients |
JP6042335B2 (ja) | 2010-09-15 | 2016-12-14 | ノヴォ ノルディスク アー/エス | 細胞取込みが低下した第viii因子変異体 |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
US10736969B2 (en) | 2010-12-21 | 2020-08-11 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
JP6009457B2 (ja) | 2010-12-23 | 2016-10-19 | ネクター セラピューティクス | ポリマー−デスエチルスニチニブコンジュゲート |
US9943605B2 (en) | 2010-12-23 | 2018-04-17 | Nektar Therapeutics | Polymer-semaxanib moiety conjugates |
EP2654799B1 (en) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Polymer-sunitinib conjugates |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
US8673448B2 (en) | 2011-03-04 | 2014-03-18 | Outlast Technologies Llc | Articles containing precisely branched functional polymeric phase change materials |
CN103608399B (zh) | 2011-04-06 | 2015-11-25 | 斯蒂潘公司 | 多臂亲水的氨基甲酸乙酯聚合物、制备它们的方法以及使用它们的组合物和方法 |
US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
EP3412314A1 (en) | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Therapeutic proteins conjugated to polysialic acid and methods of preparing same |
EA201400030A1 (ru) | 2011-06-17 | 2014-07-30 | Галозим, Инк. | Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан |
US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
US20130071394A1 (en) | 2011-09-16 | 2013-03-21 | John K. Troyer | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
US8846034B2 (en) | 2011-10-24 | 2014-09-30 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
CN104220086A (zh) | 2011-11-17 | 2014-12-17 | 塞比克斯股份公司 | Peg化的c-肽 |
WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
BR112014024291B1 (pt) | 2012-03-30 | 2022-07-05 | The Board Of Regents Of The University Of Oklahoma | Método para a produção de forma recombinante de um polímero de heparosan com alto peso molecular, uso do referido polímero para aumento de tecido, polinucleotídeo isolado e composição de material biológico compreendendo o referido polímero |
CA2869460C (en) | 2012-04-04 | 2018-05-15 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP4074728A1 (en) | 2012-08-31 | 2022-10-19 | Sutro Biopharma, Inc. | Modified peptides comprising an azido group |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
US9272075B2 (en) | 2013-02-04 | 2016-03-01 | W.L. Gore & Associates, Inc. | Coating for substrate |
ES2692150T3 (es) | 2013-02-04 | 2018-11-30 | W.L. Gore & Associates, Inc. | Revestimiento para sustrato |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
JP6463361B2 (ja) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | 第viii因子両性イオンポリマーコンジュゲート |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
HUE051389T2 (hu) | 2013-10-15 | 2021-03-01 | Seagen Inc | Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához |
WO2015104374A1 (en) * | 2014-01-10 | 2015-07-16 | Eth Zurich | Polyethylene glycol substituted acyl borates |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
PL3186281T3 (pl) | 2014-08-28 | 2019-10-31 | Halozyme Inc | Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej |
PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
KR101585795B1 (ko) * | 2014-10-14 | 2016-01-15 | 주식회사 파이토켐텍 | 활성 성분으로 디에칠렌글라이콜모노벤질에텔을 함유하는 보존제 조성물 |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
CA2968301C (en) | 2014-11-19 | 2023-05-16 | NZP UK Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
WO2016079520A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
CA2968309A1 (en) | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
TWI686401B (zh) | 2014-11-19 | 2020-03-01 | 英商Nzp英國有限公司 | 化合物(三) |
US10431858B2 (en) | 2015-02-04 | 2019-10-01 | Global Web Horizons, Llc | Systems, structures and materials for electrochemical device thermal management |
US10003053B2 (en) | 2015-02-04 | 2018-06-19 | Global Web Horizons, Llc | Systems, structures and materials for electrochemical device thermal management |
US10120948B2 (en) | 2015-10-13 | 2018-11-06 | Google Llc | Providing notifications based on geofencing search results |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
CN106905120B (zh) * | 2015-12-21 | 2020-04-28 | 北京键凯科技股份有限公司 | Y型多缩乙二醇衍生物及其制备方法 |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
EP3407917A1 (en) | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
SG11201807827VA (en) | 2016-03-25 | 2018-10-30 | Seattle Genetics Inc | Process for the preparation of pegylated drug-linkers and intermediates thereof |
GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
CN109843972B (zh) | 2016-10-07 | 2021-08-13 | 国立大学法人东京工业大学 | 分支型异单分散聚乙二醇及其制造方法和其缀合物 |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
JP2020512312A (ja) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
US10781435B2 (en) | 2017-06-22 | 2020-09-22 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
AU2018300069A1 (en) | 2017-07-11 | 2020-02-27 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
PL3849614T3 (pl) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Koniugaty polipeptydu interleukiny-2 i ich zastosowania |
JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
CN113661239A (zh) | 2018-12-28 | 2021-11-16 | 催化剂生物科学公司 | 经修饰的尿激酶型纤溶酶原激活物多肽和使用方法 |
CN114949240A (zh) | 2019-02-06 | 2022-08-30 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
EP3923991A1 (en) | 2019-02-12 | 2021-12-22 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
CN114269749A (zh) | 2019-06-10 | 2022-04-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
CN114746420A (zh) | 2019-06-17 | 2022-07-12 | 苏特罗生物制药公司 | 用于癌症治疗和诊断的作为Toll样受体(TLR)7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物 |
JP2022547078A (ja) | 2019-09-10 | 2022-11-10 | シンソークス, インコーポレイテッド | Il-2コンジュゲートおよび自己免疫疾患を治療するための使用方法 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
JP2022554272A (ja) | 2019-11-04 | 2022-12-28 | シンソークス, インコーポレイテッド | インターロイキン10コンジュゲートおよびその使用 |
US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
EP3954393A1 (en) | 2020-08-13 | 2022-02-16 | Bioasis Technologies Inc. | Combination therapies for delivery across the blood brain barrier |
KR20230073200A (ko) | 2020-08-20 | 2023-05-25 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 접합체, 그 방법 및 용도 |
WO2022103983A2 (en) | 2020-11-11 | 2022-05-19 | Sutro Biopharma, Inc. | Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use |
JP2024512775A (ja) | 2021-04-03 | 2024-03-19 | アンブルックス,インコーポレイテッド | 抗her2抗体薬物コンジュゲート及びその使用 |
AR125490A1 (es) | 2021-04-30 | 2023-07-19 | Celgene Corp | Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi) |
US20240091365A1 (en) | 2022-06-27 | 2024-03-21 | Sutro Biopharma, Inc. | Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024015229A1 (en) | 2022-07-15 | 2024-01-18 | Sutro Biopharma, Inc. | Protease/enzyme cleavable linker-payloads and protein conjugates |
WO2024044780A1 (en) | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
CN115873231A (zh) * | 2022-12-17 | 2023-03-31 | 华南理工大学 | 一种聚乙二醇修饰的氨基糖苷类分子及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0367541A (ja) | 1989-08-04 | 1991-03-22 | Meiji Milk Prod Co Ltd | 洋菓子及びコーヒー兼用のホイップ性合成クリーム |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
EP0641853B1 (en) * | 1993-08-16 | 1998-10-21 | Nalco/Exxon Energy Chemicals L.P. | Method of demulsifying water-in-oil emulsions |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
JP3067541B2 (ja) | 1994-08-23 | 2000-07-17 | 日本油脂株式会社 | グリセリンポリアルキレングリコールエーテル誘導体及びその製造方法 |
US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
DK1704878T3 (da) | 1995-12-18 | 2013-07-01 | Angiodevice Internat Gmbh | Tværbundne polymerpræparater og fremgangsmåder til deres anvendelse |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
WO1998025990A1 (fr) * | 1996-12-09 | 1998-06-18 | Daiso Co., Ltd. | Electrolyte polymere solide comprenant du copolyether |
US5746814A (en) * | 1997-05-07 | 1998-05-05 | Xerox Corporation | Decurling compositions |
US6056811A (en) * | 1997-08-25 | 2000-05-02 | Canon Kabushiki Kaisha | Water-based ink for ink-jet recording, ink-jet recording process, recording unit, ink cartridge and ink-jet recording apparatus |
JP3921781B2 (ja) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | カルボキシル基含有ポリオキシアルキレン化合物 |
ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
JP4055250B2 (ja) * | 1998-06-15 | 2008-03-05 | 日油株式会社 | アミノ基含有ポリオキシアルキレン化合物 |
US6328988B1 (en) | 1999-04-23 | 2001-12-11 | Rutgers, The State University Of New Jersey | Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
WO2001049268A1 (en) | 2000-01-05 | 2001-07-12 | Imarx Therapeutics, Inc. | Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
ATE471956T1 (de) | 2001-01-30 | 2010-07-15 | Kyowa Hakko Kirin Co Ltd | Verzweigte polyalkylenglykole |
KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
-
2002
- 2002-11-07 KR KR1020047006961A patent/KR100948532B1/ko active IP Right Grant
- 2002-11-07 MX MXPA04004336A patent/MXPA04004336A/es active IP Right Grant
- 2002-11-07 WO PCT/US2002/035759 patent/WO2003040211A2/en active Application Filing
- 2002-11-07 AU AU2002352524A patent/AU2002352524B2/en not_active Expired
- 2002-11-07 JP JP2003542253A patent/JP4758608B2/ja not_active Expired - Lifetime
- 2002-11-07 EP EP02789492A patent/EP1446438A2/en active Pending
- 2002-11-07 US US10/290,082 patent/US7026440B2/en not_active Expired - Lifetime
- 2002-11-07 CA CA2466027A patent/CA2466027C/en not_active Expired - Lifetime
-
2006
- 2006-01-20 US US11/336,695 patent/US7872072B2/en not_active Expired - Lifetime
-
2010
- 2010-12-08 US US12/963,170 patent/US8273833B2/en not_active Expired - Lifetime
-
2012
- 2012-08-24 US US13/593,861 patent/US8440816B2/en not_active Expired - Lifetime
-
2013
- 2013-04-18 US US13/865,912 patent/US8809453B2/en not_active Expired - Lifetime
-
2014
- 2014-07-17 US US14/334,223 patent/US9187569B2/en not_active Expired - Fee Related
-
2015
- 2015-10-13 US US14/882,265 patent/US20160032049A1/en not_active Abandoned
-
2019
- 2019-10-01 US US16/590,235 patent/US20200048412A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809453B2 (en) | 2001-11-07 | 2014-08-19 | Nektar Therapeutics | Branched polymers |
US9187569B2 (en) | 2001-11-07 | 2015-11-17 | Nektar Therapeutics | Branched polymers |
US8440816B2 (en) | 2001-11-07 | 2013-05-14 | Nektar Therapeutics | Branched polymers |
US8273833B2 (en) | 2001-11-07 | 2012-09-25 | Nektar Therapeutics | Branched Polymers |
US8853325B2 (en) | 2002-09-09 | 2014-10-07 | Nektar Therapeutics | Water-soluble polymer alkanals |
WO2004022630A2 (en) * | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
WO2004022630A3 (en) * | 2002-09-09 | 2004-04-15 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
US7511094B2 (en) | 2002-09-09 | 2009-03-31 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
US8076412B2 (en) | 2002-09-09 | 2011-12-13 | Nektar Therapeutics | Water-soluble polymer alkanals |
US7838595B2 (en) | 2002-09-09 | 2010-11-23 | Nektar Therapeutics | Water-soluble polymer alkanals |
US7157546B2 (en) | 2002-09-09 | 2007-01-02 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
US7462687B2 (en) | 2002-11-12 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkages |
US7273845B2 (en) | 2002-11-12 | 2007-09-25 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
WO2005000941A1 (en) * | 2003-06-05 | 2005-01-06 | Dow Global Technologies, Inc. | Novel polymer compositions |
US8436104B2 (en) | 2003-06-20 | 2013-05-07 | Warwick Effect Polymers Limited | Polymer |
JP2007501812A (ja) * | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
US8562965B2 (en) | 2004-05-03 | 2013-10-22 | Nektar Therapeutics | Polymer derivatives comprising an acetal or ketal branching point |
WO2005108463A3 (en) * | 2004-05-03 | 2006-03-30 | Nektar Therapeutics Al Corp | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
US9308273B2 (en) | 2004-05-03 | 2016-04-12 | Nektar Therapeutics | Polymer derivatives comprising an acetal or ketal branching point |
WO2005108463A2 (en) * | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ix 부분의 접합체 |
JP2008505119A (ja) * | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ,コーポレイション | 高分子−第ix因子部分の抱合体 |
NO342927B1 (no) * | 2004-06-30 | 2018-09-03 | Nektar Therapeutics | Konjugat som omfatter en Faktor IX-enhet, sammensetning av slike konjugater og fremgangsmåte for fremstilling av konjugatet. |
JP2017105820A (ja) * | 2004-06-30 | 2017-06-15 | ネクター セラピューティクス | 高分子−第ix因子部分の抱合体 |
US8586711B2 (en) | 2004-06-30 | 2013-11-19 | Nektar Therapeutics | Polymer-factor IX moiety conjugates |
KR101100059B1 (ko) * | 2004-06-30 | 2011-12-29 | 넥타르 테라퓨틱스 | 중합체인자 ix 부분의 접합체 |
JP2012025768A (ja) * | 2004-06-30 | 2012-02-09 | Nektar Therapeutics | 高分子−第ix因子部分の抱合体 |
US9347054B2 (en) | 2004-06-30 | 2016-05-24 | Nektar Therapeutics | Polymer factor IX moiety conjugates |
WO2006005058A2 (en) * | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
US7579444B2 (en) | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
WO2006005058A3 (en) * | 2004-06-30 | 2006-12-21 | Nektar Therapeutics Al Corp | Polymer-factor ix moiety conjugates |
NO20070552L (no) * | 2004-06-30 | 2007-02-14 | Nektar Therapeutics Al Corp | Polymerkonjugater av Faktor IX grupper |
EP2359842A1 (en) | 2004-07-14 | 2011-08-24 | University of Utah Research Foundation | Netrin-related compositions and uses |
JP2008506704A (ja) * | 2004-07-16 | 2008-03-06 | ネクター セラピューティクス アラバマ,コーポレイション | Gm−csf成分およびポリマーの複合体 |
WO2006019950A2 (en) * | 2004-07-16 | 2006-02-23 | Nektar Therapeutics Al, Corporation | Conjugates of a gm-csf moiety and a polymer |
WO2006019950A3 (en) * | 2004-07-16 | 2006-08-03 | Nektar Therapeutics Al Corp | Conjugates of a gm-csf moiety and a polymer |
KR101330338B1 (ko) * | 2004-07-16 | 2013-11-15 | 넥타르 테라퓨틱스 | Gm―csf 부분 및 중합체의 콘쥬게이트 |
US8357779B2 (en) | 2004-12-27 | 2013-01-22 | Baxter International Inc. | Polymer-von Willebrand factor-conjugates |
US7884075B2 (en) | 2004-12-27 | 2011-02-08 | Baxter International Inc. | Polymer-factor VIII-von Willebrand factor-conjugates |
US8835388B2 (en) | 2004-12-27 | 2014-09-16 | Baxter International Inc. | Polymer von Willebrand factor-conjugates |
US8076463B2 (en) | 2004-12-27 | 2011-12-13 | Baxter International, Inc. | Polymer-von Willebrand factor-conjugates |
AU2006319636B2 (en) * | 2005-11-30 | 2012-10-18 | Centro De Ingenieria Genetica Y Biotecnologia | Four branched dendrimer-peg for conjugation to proteins and peptides |
KR101134983B1 (ko) * | 2005-11-30 | 2012-04-09 | 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 | 단백질 및 펩티드로의 접합을 위한 4개의 분지된덴드리머-폴리에틸렌글리콜 |
US8703893B2 (en) | 2005-11-30 | 2014-04-22 | Centro De Ingenienia Genetica Y Biotecnologia | Four branched dendrimer-PEG for conjugation to proteins and peptides |
WO2007062610A3 (es) * | 2005-11-30 | 2007-09-20 | Ct Ingenieria Genetica Biotech | Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos |
US8449714B2 (en) | 2005-12-08 | 2013-05-28 | Covidien Lp | Biocompatible surgical compositions |
US8790488B2 (en) | 2005-12-08 | 2014-07-29 | Covidien Lp | Biocompatible surgical compositions |
US11020458B2 (en) | 2006-03-31 | 2021-06-01 | Takeda Pharmaceutical Company Limited | Factor VIII polymer conjugates |
US8053561B2 (en) | 2006-03-31 | 2011-11-08 | Baxter International Inc. | Pegylated factor VIII |
US8575097B2 (en) | 2009-04-23 | 2013-11-05 | Pegbio Co., Ltd. | Exendin variant and conjugate thereof |
WO2010121559A1 (zh) | 2009-04-23 | 2010-10-28 | 派格生物医药(苏州)有限公司 | 新型exendin变体及其缀合物 |
US10040761B2 (en) | 2010-06-25 | 2018-08-07 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
US20180312466A1 (en) * | 2010-06-25 | 2018-11-01 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
EP2586811A4 (en) * | 2010-06-25 | 2016-10-19 | Nof Corp | HIERÉRO-POLYETHYLENE GLYCOL BRANCHED AND INTERMEDIATE |
US10494340B2 (en) | 2010-06-25 | 2019-12-03 | Nof Corporation | Branched hetero polyethylene glycol and intermediate |
WO2012029038A1 (de) | 2010-09-01 | 2012-03-08 | Basf Se | Amphiphil zur solubilisierung schwerlöslicher wirkstoffe |
EP2611847A4 (de) * | 2010-09-01 | 2016-09-07 | Basf Se | Amphiphil zur solubilisierung schwerlöslicher wirkstoffe |
EP2947111A4 (en) * | 2013-01-17 | 2016-01-13 | Xiamen Sinopeg Biotech Co Ltd | Mono-functional Branched Polyethylene Glycol and Modified Biological Substance |
EP2896642A1 (en) * | 2014-01-16 | 2015-07-22 | Shin-Etsu Chemical Co., Ltd. | Method for producing polyalkylene glycol derivative with narrow molecular weight distribution, and acetal-group containing alcohol compound for use therein and alkali metal salt thereof |
US9284408B2 (en) | 2014-01-16 | 2016-03-15 | Shin-Etsu Chemical Co., Ltd. | Method for producing polyalkylene glycol derivative with narrow molecular weight distribution, and acetal group-containing alcohol compound for use therein and alkali metal salt thereof |
US9187404B2 (en) | 2014-01-16 | 2015-11-17 | Shin-Etsu Chemical Co., Ltd. | Method for producing polyalkylene glycol derivative having amino group at end, with narrow molecular weight distribution |
CN104109238A (zh) * | 2014-07-13 | 2014-10-22 | 成都市绿科华通科技有限公司 | 六方孔状功能聚乙二醇的制备方法 |
WO2020063628A1 (zh) | 2018-09-26 | 2020-04-02 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc融合蛋白及其缀合物 |
WO2021000767A1 (zh) | 2019-07-02 | 2021-01-07 | 郑州晟斯生物科技有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
WO2022063885A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable anti-peg antibodies in a patient |
Also Published As
Publication number | Publication date |
---|---|
US20200048412A1 (en) | 2020-02-13 |
KR20050044364A (ko) | 2005-05-12 |
US7026440B2 (en) | 2006-04-11 |
US9187569B2 (en) | 2015-11-17 |
US7872072B2 (en) | 2011-01-18 |
WO2003040211A3 (en) | 2003-07-03 |
MXPA04004336A (es) | 2005-05-16 |
US8809453B2 (en) | 2014-08-19 |
EP1446438A2 (en) | 2004-08-18 |
CA2466027A1 (en) | 2003-05-15 |
US8440816B2 (en) | 2013-05-14 |
CA2466027C (en) | 2013-01-08 |
US20120322134A1 (en) | 2012-12-20 |
US20140329994A1 (en) | 2014-11-06 |
JP4758608B2 (ja) | 2011-08-31 |
JP2005508421A (ja) | 2005-03-31 |
US20030143596A1 (en) | 2003-07-31 |
US20060178475A1 (en) | 2006-08-10 |
US20130295639A1 (en) | 2013-11-07 |
KR100948532B1 (ko) | 2010-03-23 |
AU2002352524B2 (en) | 2007-10-04 |
US20110077362A1 (en) | 2011-03-31 |
US8273833B2 (en) | 2012-09-25 |
US20160032049A1 (en) | 2016-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8809453B2 (en) | Branched polymers | |
AU2002352524A1 (en) | Branched polymers and their conjugates | |
US20100004428A1 (en) | Method of Preparing Propionic Acid-Terminated Polymers | |
US10421838B2 (en) | Methods for preparing polymeric reagents and compositions of polymeric reagents | |
EP1476489B1 (en) | Hydrolytically degradable alkylene oxide based polymers | |
MXPA06008321A (en) | Method of preparing propionic acid-terminated polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002352524 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2466027 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/004336 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003542253 Country of ref document: JP Ref document number: 1020047006961 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002789492 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002789492 Country of ref document: EP |